Literature DB >> 2443620

Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer.

J V Sitzmann1, S E Order, J L Klein, P K Leichner, E K Fishman, G W Smith.   

Abstract

Eleven patients with hepatocellular cancer had nonresectable lesions, ten as determined by laparotomy and one by computed tomographic (CT) evidence of inferior vena caval invasion. These patients were treated with a variety of new modalities, particularly radiolabeled antiferritin antibodies. Following treatment, seven of the 11 patients were considered to have converted their lesions to possible resectability. Six patients had complete resections, and one patient was partially resected. All patients had the common features of either nodular massive or nodular multifocal hepatocellular cancer. Relative to the patient's initial status, the quality of life remains high, and a new approach in the treatment of the nodular form of nonresectable hepatoma has been demonstrated. The present rate of such conversion to resectability is unknown. However, with further advances in radiolabeled antibody therapy, these results offer a new opportunity in the management of hepatocellular cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2443620     DOI: 10.1200/JCO.1987.5.10.1566

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  9 in total

1.  Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.

Authors:  Minaxi Jhawer; Lee Rosen; Janet Dancey; Howard Hochster; Solomon Hamburg; Margaret Tempero; Neil Clendeninn; Sridhar Mani
Journal:  Invest New Drugs       Date:  2006-09-07       Impact factor: 3.850

2.  The role of liver transplantation in hepatobiliary malignancy. A retrospective analysis of 95 patients with particular regard to tumor stage and recurrence.

Authors:  B Ringe; C Wittekind; W O Bechstein; H Bunzendahl; R Pichlmayr
Journal:  Ann Surg       Date:  1989-01       Impact factor: 12.969

Review 3.  Vascular and interstitial barriers to delivery of therapeutic agents in tumors.

Authors:  R K Jain
Journal:  Cancer Metastasis Rev       Date:  1990-11       Impact factor: 9.264

Review 4.  Liver transplantation for hepatocellular carcinoma: clinical results and future aspects.

Authors:  R Pichlmayr; A Weimann; G Steinhoff; B Ringe
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Improved survival for hepatocellular cancer with combination surgery and multimodality treatment.

Authors:  J V Sitzmann; R Abrams
Journal:  Ann Surg       Date:  1993-02       Impact factor: 12.969

Review 6.  Conversion of unresectable to resectable liver cancer: an approach and follow-up study.

Authors:  J V Sitzmann
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

7.  Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: evaluation with analysis of 72 patients.

Authors:  Z Y Tang; Y Q Uy; X D Zhou; Z C Ma; J Z Lu; Z Y Lin; K D Liu; S L Ye; B H Yang; H W Wang
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

8.  Treatment of unresectable primary liver cancer: with reference to cytoreduction and sequential resection.

Authors:  Z Y Tang; Y Q Yu; X D Zhou; Z C Ma; B H Yang; Z Y Lin; J Z Lu; K D Liu; Z Fan; Z C Zeng
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

9.  Successful conversion therapy for unresectable hepatocellular carcinoma is getting closer: A systematic review and meta-analysis.

Authors:  Yinxuan Pei; Weiwei Li; Zixiang Wang; Jinlong Liu
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.